Immunogenicity of intramuscular fractional dose of inactivated poliovirus vaccine.
Intradermal (id) fractional Inactivated Poliovirus Vaccine (fIPV, 1/5th of normal IPV dose) is safe and immunogenic, however, id administration is perceived as difficult. We compared fIPV immunogenicity administered id or intramuscularly (im). This non-inferiority trial was conducted among polio-vaccine naïve Cuban infants who received two IPV doses at 4 and 8 months of age. Infants were randomized into four arms-A: fIPV 0.1mL im; B: fIPV 0.2mL im; C: fIPV 0.1mL id; D: IPV 0.5mL im. Blood collected before and after vaccinations was tested for poliovirus neutralizing antibodies. 196/214 (91.6%) enrolled children completed study. Seroconversion after two IPV doses in arm A was 97.3% (90.6-99.7), 98.7% (92.7-99.9), 90.5% (81.5-96.1) for serotypes 1, 2, 3 respectively; B: 97.2% (90.3-99.7),100%, 95.8% (88.3-99.1); C: 89.3% (71.8-97.7), 92.9% (76.5-99.1), 82.1% (63.1-93.9); D: 100%, 100%, 100%. Seroconversion with fIPV im was non-inferior to fIPV id for all serotypes. We demonstrated non-inferiority of fIPV im compared to id when administered at 4 and 8 months of age. Further investigations in an earlier infant schedule should be pursued to explore fIPV im as option for dose-sparing strategy in countries reluctant to use fIPV id due to programmatic difficulties of intradermal administration.